Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 15/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5453351 | 0.70 | RXFP1 (0.49) | MEN1KMT2AL3MBTL1 | |
| SCHEMBL5450911 | 0.70 | L3MBTL1 (0.47) | MEN1KMT2AKDM4EMAPTL3MBTL1 | |
| SCHEMBL10591324 | 0.69 | PLA2G2A (0.65) | PLA2G2APTGS2 | |
| SCHEMBL19292039 | 0.69 | PLA2G2A (0.65) | PLA2G2APTGS2 | |
| SCHEMBL7953425 | 0.66 | PLA2G2A (0.70) | PLA2G2APTGS2 | |
| SCHEMBL6429124 | 0.65 | PTGS2 (0.77) | PLA2G2AMEN1KMT2APTGS2KDM4E | |
| SCHEMBL17385243 | 0.65 | PTGS2 (0.84) | PLA2G2AMEN1KMT2APTGS2KDM4E | |
| SCHEMBL2101660 | 0.64 | KDM4E (1.00) | MEN1KMT2AKDM4EMAPTRECQL | |
| SCHEMBL5457874 | 0.64 | KMT2A (0.44) | MEN1KMT2AKDM4EMAPTL3MBTL1 | |
| SCHEMBL7964650 | 0.64 | PLA2G2A (1.00) | PLA2G2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | claimed |
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | GPC BIOTECH AG (DE) | 2007-11-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070275962-A1 | Heterobicyclic Compounds as Pharmaceutically Active Agents | TBCA, PARK7, NFATC1 | PLA2G2A 4831/4885MEN1 2891/4885KMT2A 4785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.